Visionaries of Medical Innovation: 2021 China Smart Diagnostics Medicine Ranking Opens for Nominations!

Looking at the present moment, we can clearly see that diagnostic medicine is entering a new era of intelligence, surging with innovation.

From a global perspective, the digital and intelligent transformation of the healthcare industry is accelerating toward the technological frontier. Driven by multiple factors—including policy support, technological iteration, and the global impact of the pandemic—the diagnostic medicine industry is embracing the digital-intelligent era with unprecedented momentum. Innovative digital-intelligent technologies are shaping a new future for the smart diagnostic medicine industry. In this context, it is even more critical to identify visionaries in medical innovation, consolidate innovative forces, and empower the future of the industry.

Vision begins with what is within sight, fromHigh-End Medical Imaging Equipment、Digital Intelligent Assisted Diagnosis、Innovative In Vitro Diagnostics—High-Throughput SequencingStarting from three value dimensions, identify and select the most representative and high-growth innovative enterprises of the year.“2021 China Smart Diagnostic Medicine List”。

Click the image to submit your nomination for the ranking.

China Smart Diagnostic Medicine ListGuided and promoted by the Science and Technology Commission of Baoshan District, Shanghai, and the Administrative Committee of Shanghai Baoshan High-Tech Industrial Park,Baoshan Smart Diagnostic Medicine R&D and Translation Functional Platform, VB100, VCBeat, Eggshell Research InstituteA domestically launched ranking list for private companies in the field of smart diagnostic medicine, aimed at selecting Chinese innovators who truly represent the future of smart diagnostic medicine, identifying the core forces driving China’s future smart diagnostic medicine industry, promoting innovation and transformation in the sector, and supporting scientific research exploration and clinical medical practice.

The China Smart Diagnostics Medicine List will solicit and select the most representative and high-growth innovative enterprises in each value domain from global practitioners in the smart diagnostics medicine industry. The selection will focus on multiple value areas that have attracted the most attention from scientific research, clinical medicine, and investment institutions during the year. Based on clinical practical application and capital interest as primary criteria, the evaluation will also incorporate three additional factors: media focus, annual data热度 of medical and health enterprise performance, and future industry development prospects.

The 2021 China Smart Diagnostic Medicine List will be selected fromHigh-end Medical Imaging Equipment, Digital Intelligent Assisted Diagnosis, and Innovative In Vitro Diagnostics—High-Throughput SequencingSelected across three value domains, with a primary focus on the annual performance of participating companies in areas such as R&D teams, R&D investment, R&D methodologies, areas of focus, progress of products under development, performance of launched products, and clinical application practices.

Medical imaging provides crucial scientific and visual evidence for disease diagnosis. By integrating patients’ clinical symptoms and laboratory test results, it plays an irreplaceable role in achieving accurate final diagnoses. It enables clinicians to make precise diagnoses, thereby facilitating the formulation of appropriate treatment plans, evaluating therapeutic efficacy, providing a basis for staged treatment, and conducting post-treatment follow-up observations and monitoring.

Selection Criteria:Primarily covers R&D, manufacturing, and service providers of medical imaging equipment for hospital use, including but not limited to PET, PET-CT, MR, MRI, ultrasound, and DR.

Eligibility Requirements:A. Non-listed companies in the field; B. Capability for sustainable operations; C. Technology-driven innovative enterprises; D. Having secured at least angel-round financing; E. Maintaining physical entities and business operations in China; F. Still operational as of the evaluation date; G. No major corporate violations within the past three years.

Since 2015, China has successively introduced a series of policies to promote the development of artificial intelligence (AI) in the healthcare sector, which have played a pivotal guiding role in the application and implementation of AI in disease diagnosis and treatment. By leveraging AI’s efficient learning capabilities and data analysis and processing functions to provide precise decision-making recommendations, clinicians can be effectively assisted in keeping pace with disease progression and addressing clinical challenges with greater proficiency and confidence.

Eligible Candidates:Service providers offering intelligent auxiliary services/solutions for medical application scenarios such as early screening, clinical diagnosis, and prognostic follow-up assessment, including but not limited to radiology and pathology.

Eligibility Requirements:A. Non-listed companies in the field; B. Capability for sustained operations; C. AI algorithm innovation-driven enterprises; D. Having secured at least angel-round financing; E. Possessing physical entities and business operations in China; F. Still operational as of the evaluation date; G. No major corporate violations within the past three years.

Amid the booming development of precision medicine, molecular diagnostics are playing an increasingly important role due to their unique advantages. As the biochemical diagnostics market approaches saturation, molecular diagnostics are poised to become the next major investment hotspot, ushering in a period of rapid growth. Next-generation sequencing (NGS), as an emerging molecular diagnostic technology, enables the simultaneous detection of multiple genetic loci. It offers significant advantages in tumor companion diagnostics and demonstrates prominent strengths in various fields such as liquid biopsy and tumor genetic testing, with its clinical value now widely recognized.

Eligible Candidates:Primarily covers innovative R&D enterprises specializing in high-throughput sequencing instruments, assay reagents, clinical applications, and technology platforms.

Eligibility Requirements:A. Non-listed companies in the field; B. Capable of sustained operations; C. Technology-innovative enterprises; D. Having secured at least angel-round financing; E. Maintaining physical entities and business operations in China; F. Still operational as of the evaluation date; G. No major corporate violations committed within the past three years.

2021 China Smart Diagnostic Medicine Ranking will adopt the Four-Dimensional Vitality Matrix of Value to comprehensively evaluate and score enterprises across four primary dimensions—core competitiveness, key partners, industry performance, and innovation vitality—based on 13 secondary indicators: knowledge resources, human resources, brand image resources, star products, research collaborations, channel partnerships, industry scale, market share, user base, value chain position, technological innovation, scenario-based innovation, and material innovation.

From today through November 30: Open Registration for the Rankings

December 1–December 6: Professional Jury Ranking Selection and Information Verification

January 9, 2022: On-site Announcement of the Inaugural “China Smart Diagnostic Medicine List” at the 2021 Forum on the Translation of Smart Diagnostic Achievements and Industrial Innovation (Shanghai, Baoshan)

Participation Link: http://vcbeat-vb100.mikecrm.com/3ITVfnz

The form contains extensive text; it is recommended to complete it on a PC. A VCBeat VB100 representative will contact you within two business days.

Welcome to scan the QR code to register!

Online article dissemination to increase the exposure of listed companies, with recommendations across the entire VCBeat VB100 community resources, and provision of industry/capital matchmaking services post-publication.

Centered on “Smart Diagnostics,” this forum focuses on hot topics such as the digital transformation of the diagnostics industry, the development of smart diagnostic systems, and the clinical value of digital smart diagnostics, while exploring the latest industry trends and future frontier technologies in smart diagnostic medicine.

Conference Time: January 9, 2022 (Sunday) 9:30-17:00

Conference Venue: Shanghai • Baoshan District • Jiusi Hotel

Registration Link: http://hdxu.cn/ISEa6

We had the opportunity to be invited to participate in the industry seminars held concurrently with the forum, engaging in discussions and interactions with policy and industry experts from Shanghai on topics such as the support needed for enterprise development and the strategic planning of the intelligent diagnostic medicine industry.

Focusing on the digital transformation and technological innovation of the smart diagnostics industry, this session provides in-depth insights into development trends, the evolution of cutting-edge technologies, AI-assisted diagnosis, tumor immuno-oncology diagnosis and treatment, pathology-driven pharmaceutical R&D, and the localization of in vitro diagnostics.

Anchored in industry research, VCBeat identifies the most representative and high-growth innovative enterprises of the year within the smart diagnostics sector. By tracking innovations, technological advancements, and policy updates, VCBeat focuses on three key value domains: high-end medical imaging equipment, digital AI-assisted diagnosis, and innovative in vitro diagnostics—specifically high-throughput sequencing.

The China Smart Diagnostic Medicine List will be announced at the 2021 Forum on the Transformation of Smart Diagnostic Achievements and Industrial Innovation, and will be promoted through VCBeat’s online media matrix.

Centered on a “1+1+1” framework, this forum features one online call-for-entries and selection event, one awards announcement ceremony, and one Smart Diagnostics Innovation Industry Forum, bringing together 50+ industry representatives to jointly explore innovative development in the field of smart diagnostics.

The conference will invite distinguished guests, including academicians, leaders from national ministries and commissions, scientific research experts, hospital directors, clinical specialists, and leaders of innovative enterprises. Focusing on topics such as the opportunities and challenges facing the smart diagnostics industry, corporate development, and collaboration among industry, academia, and research institutions, participants will jointly explore industry growth and cooperation from multiple dimensions and perspectives, including policy, technology, market, and capital.